Collegium Pharmaceutical, Inc. reported record financial results for the fourth quarter and full year ended December 31, 2024. Quarterly net revenue reached $181.9 million, contributing to a full-year net revenue of $631.4 million. This represents an 11% increase in total revenue for the year.
Jornay PM generated quarterly net revenue of $29.3 million and pro forma full-year net revenue of $100.7 million, establishing its presence in neuropsychiatry. GAAP net income for the quarter was $12.5 million, with full-year GAAP net income at $69.2 million. Adjusted EBITDA reached a record $107.7 million for the quarter and $401.2 million for the full year, an increase of 9% year-over-year.
The company ended 2024 with $162.8 million in cash, cash equivalents, and marketable securities. Collegium also repurchased $60.0 million in shares during 2024, demonstrating its commitment to shareholder value. The full-year 2025 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA was reaffirmed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.